Abstract:Hypertension represents one of the primary and most common risk factors leading to the development of heart failure (HF) across the entire spectrum of left ventricular ejection fraction. A large body of evidence has demonstrated that adequate blood pressure (BP) control can reduce cardiovascular events, including the development of HF. Although the pathophysiological and epidemiological role of hypertension in the development of HF is well and largely known, some critical issues still deserve to be clarified, including BP targets, particularly in HF patients. Indeed, the management of hypertension in HF relies on the extrapolation of findings from high-risk hypertensive patients in the general population and not from specifically designed studies in HF populations. In patients with hypertension and HF with reduced ejection fraction (HFrEF), it is recommended to combine drugs with documented outcome benefits and BP-lowering effects. In patients with HF with preserved EF (HFpEF), a therapeutic strategy with all major antihypertensive drug classes is recommended. Besides commonly used antihypertensive drugs, different evidence suggests that other drugs recommended in HF for the beneficial effect on cardiovascular outcomes exert advantageous blood pressure-lowering actions. In this regard, type 2 sodium glucose transporter inhibitors (SGLT2i) have been shown to induce BP-lowering actions that favorably affect cardiac afterload, ventricular arterial coupling, cardiac efficiency, and cardiac reverse remodeling. More recently, it has been demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Other proposed agents, such as endothelin receptor antagonists, have provided contrasting results in the management of hypertension and HF. A novel, promising strategy could be represented by small interfering RNA, whose actions are under investigation in ongoing clinical trials.

Left ventricular hypertrophy as a target of treatment in patients with hypertension.

Prevention and treatment of hypertensive left ventricular hypertrophy

Progress in diagnosis and treatment of hypertension combined with left ventricular hypertrophy

Effects of Obesity on the Left Ventricular Hypertrophyin Patients with Hypertension

Left ventricular hypertrophy in acute stroke patients with known hypertension

Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials

Effect of Long-term Intensive Blood Pressure Control on Left Ventricular Hypertrophy in High Risk Hypertensive Patients

Ambulatory blood pressure is associated with left ventricular geometry after 10 years in hypertensive patients with continuous antihypertensive treatment

Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension

Hypertension and its association to phenotype on left ventricular function in hypertrophic cardiomyopathy patients assessed by cardiovascular magnetic resonance imaging

Blood pressure in heart failure management and prevention

Target Blood Pressure and Control Status in Asia

Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial

Hypertension and Heart Failure: From Pathophysiology to Treatment

Left Ventricular Hypertrophy and Ventricular Arrhythmia

Value of Electrocardiographic Left Ventricular Hypertrophy As a Predictor of Poor Blood Pressure Control

Regression of left ventricular hypertrophy

Hypertrophic Cardiomyopathy and Left Ventricular Hypertrophy in Hypertensive Heart Disease with Mildly Reduced or Preserved Ejection Fraction: Insight from Altered Mechanics and Native T1 Mapping.

Layer-specific Quantification of Myocardial Deformation May Disclose the Subclinical Systolic Dysfunction and the Mechanism of Preserved Ejection Fraction in Patients with Hypertension.

Risk Factors Related to Left Ventricular Hypertrophy in Elderly Hypertensive Patients

The Effect of Hypertension on Cardiac Structure and Function in Different Types of Hypertrophic Cardiomyopathy: A Single-Center Retrospective Study